

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 January 2019 (17.01.2019)



(10) International Publication Number
WO 2019/014492 A1

(51) International Patent Classification:

A61K 31/47 (2006.01) C07C 13/48 (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:

PCT/US2018/041892

(22) International Filing Date:

12 July 2018 (12.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/532,233 13 July 2017 (13.07.2017) US
62/552,814 31 August 2017 (31.08.2017) US

(71) Applicant: **IO THERAPEUTICS, INC.** [US/US]; 1805
East Garry Avenue, Santa Ana, California 92705 (US).

(72) Inventors: **CHANDRARATNA, Roshantha A.**; 26242
Via Corrizo, San Juan Capistrano, California 92675 (US).
SANDERS, Martin E.; c/o Io Therapeutics, INC., 1920 4th
Avenue, #2704, Seattle, Washington 98101 (US).

(74) Agent: **CULLMAN, Louis C.** et al.; K&L Gates LLP, 1
Park Plaza, Twelfth Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: IMMUNOMODULATORY RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MOD-
ULATORS FOR CANCER IMMUNOTHERAPY




FIG. 1

(57) Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

WO 2019/014492 A1